Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

← catalyst calendar

NCT06163534 · readout in 559 d

Sponsored by Tempus AI (industry) · TEM — their whole pipeline →. With AstraZeneca.

Phase
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
30
Countries
Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-08-01actualWhen the study began enrolling
Primary completion2028-03-01estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-03-01estimatedThe whole study's end, after follow-up
First posted2023-12-11actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-12actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Head and Neck Squamous Cell Carcinoma

Primary outcome

what the primary-completion date above is the date OF
Explore DNA, RNA, immune and other multiomic biomarkers to better understand prognostic or predictive biomarkers and to inform future research for new relevant biomarkers.
measured 5 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · TEM's whole pipeline · Catalyst calendar · Every registered study · What changed